UNCY - CONSENSUS CO - Unicycive Therapeutics

Unicycive Therapeutics (UNCY) aims to capture a significant share of the nephrology market through the implementation of Oxylanthanum Carbonate following FDA approval. The company's operations are shielded from geopolitical risks due to its US legal status and the humanitarian nature of its developments. This price action chart, featuring the current metric 29.49, illustrates the quotes of an asset whose business relies on creating indispensable phosphate control agents for dialysis.

This indicator represents a weighted average fair value estimate of the shares, synthesized from forecasts by leading investment houses to determine the security's fundamental potential. For Unicycive Therapeutics (UNCY), the consensus target price history reflects market expectations regarding the success of clinical trials and the search for a commercial partner, rendering the equity sensitive to any changes in the drug development timeline.